Ovid Makes Two New Appointments
This article was originally published in Scrip
Ovid Therapeutics has appointed Amit Rakhit chief medical and portfolio management officer and Daniel H. Geschwind to the company's scientific advisory board. Prior to Ovid, Rakhit was senior vice president, head of worldwide medical at Biogen and he was also vice president, program leadership and management at Biogen. Previously he held leadership roles at Bristol-Myers Squibb including director, cardiovascular R&D and executive medical director, cardiovascular/metabolics. Recently Geschwind was appointed senior associate dean and associate vice chancellor of precision medicine in the UCLA Health System and David Geffen School of Medicine. He is a professor of neurology and psychiatry and biobehavioral sciences at the UCLA School of Medicine and director of the Center for Autism Research and Treatment (CART) and co-director of the center for neurobehavioral genetics at UCLA.
Register for our free email digests: